
FDA commissioner Scott Gottlieb says that more rigorous approval process would be unique to opioids
pharmafile | November 12, 2018 | News story | Sales and Marketing | FDA, Gottlieb, opioid crisis, opioids
Food and Drug Administration (FDA) commissioner Scott Gottlieb has said that if a more rigorous approval process is introduced for opioids, the higher standards will be ‘unique’ to opioids.
“I don’t think this same kind of standard would apply in other therapeutic areas. I think opioids are unique,” Gottlieb said.
The suggestion comes in the midst of a debate as to whether new drugs should be approved or rejected within the context of what is already available on the market. Although currently, drugs are approved only on the basis as to whether the medicine is safe and effective, this could change in regards to opioids.
The change may mean that new opioids would have to bring some distinct value to the market in order to be approved.
Gottlieb added: “I would do everything that I could from a policy standpoint … to make it explicit that this was narrowly tailored to opioids for public health reasons”
Louis Goss
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …




